Lamivudina + Zidovudina Aurobindo (Zidovudine, Lamivudine)

Lamivudine is a nucleoside reverse transcriptase inhibitor that, after intracellular phosphorylation, mimics natural nucleosides and is incorporated into viral DNA by HIV reverse transcriptase. This incorporation halts DNA chain elongation, leading to premature termination of viral replication.

The dosage of Lamivudina + Zidovudina is individualized by the prescribing clinician based on factors such as the patient’s age, weight, renal and hepatic function, and the overall antiretroviral regimen. No fixed dose can be stated without a medical prescription.

Safety data for Lamivudina + Zidovudina in pregnancy and lactation are limited. The medication should be used only if the potential benefits to the mother outweigh any possible risks to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lamivudina + Zidovudine offers a dual‑NRTI backbone that is well‑studied, generally well‑tolerated, and compatible with many other antiretroviral classes. Compared with newer agents, it may have a more established safety profile but can be associated with mitochondrial toxicity, requiring monitoring for lactic acidosis and peripheral neuropathy.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use.

The medication is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse events include lactic acidosis, severe neutropenia, hepatotoxicity, hypersensitivity reactions, and pancreatitis. Patients should be educated to seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, severe fatigue, or signs of infection.

Individuals with known hypersensitivity to lamivudine, zidovudine, or any excipients in the formulation should avoid the product. Caution is also advised for patients with severe hepatic or bone‑marrow impairment, as the drug may exacerbate these conditions.